XORTX Therapeutics Return on Equity

XORTX Therapeutics (XRTX) currently reports a ROE of -71.12%. That is below the Materials sector average of 19.67%. Use the charts on this page to explore XORTX Therapeutics's ROE history and peer comparisons.

XORTX Therapeutics's ROE of -71.12% is lower than the Materials sector average of 19.67%. That is roughly 461.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but XORTX Therapeutics's current -71.12% should be judged against Materials norms (sector average: 19.67%) and against XRTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -71.12%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Materials average is 19.67%. From there, open related valuation or income-statement pages for XORTX Therapeutics, and consider following XRTX for alerts when major investors trade the stock.

XORTX Therapeutics is classified in the Materials sector. On ROE, it currently shows -71.12% versus a sector average near 19.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Materials are usually more informative than comparing XRTX with unrelated industries.